HOUSTON -- CytoGenix Inc. announced that it has entered into an agreement with the Section of Pediatric Infectious Diseases of Baylor College of Medicine for mice and cell studies using the company's new antimicrobial agent against a highly dangerous strain of Staphylococcus aureus bacteria.
The Centers for Disease Control and Prevention (CDC) report, "Strains of methicillin-resistant Staphylococcus aureus (MRSA), which had been largely confined to hospitals and long-term care facilities, are emerging in the community. The changing epidemiology of MRSA bears striking similarity to the emergence of penicillinase-mediated resistance in S. aureus decades ago. Even though the origin (hospital or the community) of the emerging MRSA strains is not known, the prevalence of these strains in the community seems likely to increase substantially."
Dr. Sheldon Kaplan, professor of pediatrics at Baylor and chief of service at Texas Children's Hospital Infectious Diseases Center, states, "We are seeing a significant increase in the number of children with community-acquired MRSA infection. A very resistant bug is infecting children in this region of the country. For this reason, we are interested in the results of these experiments with the CytoGenix compound."
Dr. Edward Mason, professor, and Dr. Jesus Vallejo, assistant professor, both in the department of pediatrics infectious diseases section at Baylor, will conduct studies to determine the effect of this novel compound on this strain of MRSA.
"Our antimicrobial product certainly addresses an important medical need, and we welcome the opportunity to collaborate with leading clinicians and scientific investigators to demonstrate its activity against difficult targets," states Dr. Malcolm Skolnick, CytoGenix, chairman and CEO.
Source: CytoGenix Inc.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.